{"id":957694,"date":"2026-05-04T16:05:16","date_gmt":"2026-05-04T20:05:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"},"modified":"2026-05-04T16:05:16","modified_gmt":"2026-05-04T20:05:16","slug":"hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","title":{"rendered":"Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May  04, 2026  (GLOBE NEWSWIRE) &#8212;  Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the closing of its initial public offering of 19,262,500 shares of its common stock at a public offering price of $18.00 per share, including 2,512,500 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were sold by Hemab. Hemab\u2019s common stock began trading on the Nasdaq Global Select Market on Friday, May 1, 2026 under the ticker symbol \u201cCOAG.\u201d The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Hemab, were approximately $346.7 million.<\/p>\n<p>Goldman Sachs &amp; Co. LLC, Jefferies and Evercore ISI acted as joint book-running managers for the offering. Wedbush PacGrow acted as lead manager for the offering.<\/p>\n<p>A registration statement relating to the securities sold in the offering was filed with the\u00a0Securities and Exchange Commission (SEC) and was declared effective on April 30, 2026. Copies of the registration statement can be accessed through the SEC\u2019s website at\u00a0www.sec.gov. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from\u00a0Goldman Sachs &amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.<\/p>\n<p>This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.<\/p>\n<p>\n        <strong>About Hemab Therapeutics<\/strong>\n      <\/p>\n<p>Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab\u2019s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Deerfield<br \/>Peg Rusconi <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q83L0u5EyDNumpOluFRcAGoDfV9wC7BJcZ2TfzxEk_tCa0R3pAbBW40aOhp_wxC5AVaaTQnG8WUfesag5zKHU92l3DNqAQ5aeHeVxzxkWc8Fr7slIYV4mwbGfsqY9wxL\" rel=\"nofollow\" target=\"_blank\">peg.rusconi@deerfieldgroup.com<\/a><\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Hemab Therapeutics<br \/>Mads Behrndt<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Yd-zBqY8lCt-YUrOXAiP0xENvvcRgzRCcP5yk6v7T-GTXu4zIGzmyr__9iLOtQCa80fCLw0DToO7UfjeiLQ4RjmA2CVQU08UBKycVW4LD6A=\" rel=\"nofollow\" target=\"_blank\">investors@hemab.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU4MiM3NTgxNjE0IzIzMTAyNzE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2UyM2ExNWYtYTJjYi00M2RhLTkwZGEtNjZlYTUyMzI4NTI4LTEzMjE4MjEtMjAyNi0wNS0wNC1lbg==\/tiny\/Hemab-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) &#8212; Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the closing of its initial public offering of 19,262,500 shares of its common stock at a public offering price of $18.00 per share, including 2,512,500 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were sold by Hemab. Hemab\u2019s common stock began trading on the Nasdaq Global Select Market on Friday, May 1, 2026 under the ticker symbol \u201cCOAG.\u201d The gross proceeds &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-957694","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) &#8212; Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the closing of its initial public offering of 19,262,500 shares of its common stock at a public offering price of $18.00 per share, including 2,512,500 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were sold by Hemab. Hemab\u2019s common stock began trading on the Nasdaq Global Select Market on Friday, May 1, 2026 under the ticker symbol \u201cCOAG.\u201d The gross proceeds &hellip; Continue reading &quot;Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-04T20:05:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU4MiM3NTgxNjE0IzIzMTAyNzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares\",\"datePublished\":\"2026-05-04T20:05:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\"},\"wordCount\":507,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjU4MiM3NTgxNjE0IzIzMTAyNzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\",\"name\":\"Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjU4MiM3NTgxNjE0IzIzMTAyNzE=\",\"datePublished\":\"2026-05-04T20:05:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjU4MiM3NTgxNjE0IzIzMTAyNzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjU4MiM3NTgxNjE0IzIzMTAyNzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","og_locale":"en_US","og_type":"article","og_title":"Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk","og_description":"CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) &#8212; Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the closing of its initial public offering of 19,262,500 shares of its common stock at a public offering price of $18.00 per share, including 2,512,500 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were sold by Hemab. Hemab\u2019s common stock began trading on the Nasdaq Global Select Market on Friday, May 1, 2026 under the ticker symbol \u201cCOAG.\u201d The gross proceeds &hellip; Continue reading \"Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-04T20:05:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU4MiM3NTgxNjE0IzIzMTAyNzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","datePublished":"2026-05-04T20:05:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"},"wordCount":507,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU4MiM3NTgxNjE0IzIzMTAyNzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","name":"Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU4MiM3NTgxNjE0IzIzMTAyNzE=","datePublished":"2026-05-04T20:05:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU4MiM3NTgxNjE0IzIzMTAyNzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjU4MiM3NTgxNjE0IzIzMTAyNzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=957694"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957694\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=957694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=957694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=957694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}